Stockscreener 앱 받기
19.46
5.93%
1.09
전일 마감가:
$18.37
열려 있는:
$18.51
하루 거래량:
1.95M
Relative Volume:
1.62
시가총액:
$1.69B
수익:
$203.45M
순이익/손실:
$-351.45M
주가수익비율:
-4.2769
EPS:
-4.55
순현금흐름:
$-369.41M
1주 성능:
+14.00%
1개월 성능:
+13.27%
6개월 성능:
+98.57%
1년 성능:
+122.65%
1일 변동 폭
$18.51
$19.76
1주일 범위
$17.32
$19.76
52주 변동 폭
$5.12
$20.33
Travere Therapeutics Inc Stock (TVTX) Company Profile
명칭
Travere Therapeutics Inc
전화
888-969-7879
주소
3611 VALLEY CENTRE DR, SAN DIEGO
TVTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
19.46 | 1.69B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-21 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-09 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-03-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-12-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-11-20 | 개시 | Citigroup | Neutral |
| 2023-09-22 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | 재개 | Evercore ISI | Outperform |
| 2023-07-21 | 개시 | JP Morgan | Overweight |
| 2023-06-07 | 재개 | Piper Sandler | Neutral |
| 2023-05-22 | 개시 | TD Cowen | Outperform |
| 2023-05-05 | 업그레이드 | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-21 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-12-14 | 개시 | Stifel | Hold |
| 2022-12-05 | 개시 | Wells Fargo | Overweight |
| 2022-09-21 | 개시 | Bryan Garnier | Sell |
| 2022-07-14 | 재개 | Canaccord Genuity | Buy |
| 2022-03-31 | 개시 | Piper Sandler | Overweight |
| 2022-02-28 | 개시 | H.C. Wainwright | Buy |
| 2021-05-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
모두보기
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Cantor Fitzgerald Predicts TVTX FY2025 Earnings - MarketBeat
What is Leerink Partnrs’ Estimate for TVTX FY2026 Earnings? - Defense World
Leerink Partnrs Issues Optimistic Estimate for TVTX Earnings - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World
Research Analysts Issue Forecasts for TVTX FY2024 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for TVTX Earnings - MarketBeat
What is HC Wainwright’s Estimate for TVTX FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for TVTX Issued By HC Wainwright - MarketBeat
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart
Alport Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.2%Here's Why - MarketBeat
Travere Therapeutics Provides Corporate Update and 2025 Outlook - The Manila Times
Travere's FILSPARI Drives $50M Q4 Sales, European Expansion Gains Momentum with Multi-Country Launch - StockTitan
Travere Therapeutics (NASDAQ:TVTX) Coverage Initiated at Cantor Fitzgerald - Defense World
Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade - MSN
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 2,066 Shares of Stock - MarketBeat
Travere therapeutics chief medical officer sells shares totaling $47,714 By Investing.com - Investing.com Canada
Travere therapeutics chief medical officer sells shares totaling $47,714 - Investing.com
Travere Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Travere Therapeutics (NASDAQ:TVTX) Trading Up 7.2%Here's Why - MarketBeat
High Growth Tech Stocks in the United States to Watch - Simply Wall St
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Geode Capital Management LLC Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Geode Capital Management LLC - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $258,300.00 in Stock - MarketBeat
Travere therapeutics CAO Calvin Sandra sells $258,277 in stock By Investing.com - Investing.com Canada
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain - Yahoo Finance
Barclays PLC Sells 17,544 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
State Street Corp Has $38.29 Million Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - The Eastern Progress Online
XTX Topco Ltd Cuts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics' SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Canada
(TVTX) Investment Analysis - Stock Traders Daily
Y Intercept Hong Kong Ltd Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Fmr LLC Acquires 31,772 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
The Manufacturers Life Insurance Company Purchases 17,931 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics' SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Canada
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
Charles Schwab Investment Management Inc. Sells 1,184 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Two Sigma Advisers LP Increases Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lessened by Point72 Asia Singapore Pte. Ltd. - MarketBeat
Travere Therapeutics Inc (TVTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):